Immunohistochemical evaluation of p16 expression in cutaneous histiocytic, fibrohistiocytic and undifferentiated lesions
dc.contributor.author | Smith, Emily H. | |
dc.contributor.author | Lowe, Lori | |
dc.contributor.author | Harms, Paul W. | |
dc.contributor.author | Fullen, Douglas R. | |
dc.contributor.author | Chan, May P. | |
dc.date.accessioned | 2016-09-17T23:53:36Z | |
dc.date.available | 2017-11-01T15:31:29Z | en |
dc.date.issued | 2016-08 | |
dc.identifier.citation | Smith, Emily H.; Lowe, Lori; Harms, Paul W.; Fullen, Douglas R.; Chan, May P. (2016). "Immunohistochemical evaluation of p16 expression in cutaneous histiocytic, fibrohistiocytic and undifferentiated lesions." Journal of Cutaneous Pathology 43(8): 671-678. | |
dc.identifier.issn | 0303-6987 | |
dc.identifier.issn | 1600-0560 | |
dc.identifier.uri | https://hdl.handle.net/2027.42/133546 | |
dc.publisher | Blackwell Publishing Ltd | |
dc.publisher | Wiley Periodicals, Inc. | |
dc.subject.other | non‐Langerhans cell | |
dc.subject.other | p16 protein | |
dc.subject.other | immunohistochemistry | |
dc.subject.other | melanocytic lesions | |
dc.subject.other | histiocytosis | |
dc.title | Immunohistochemical evaluation of p16 expression in cutaneous histiocytic, fibrohistiocytic and undifferentiated lesions | |
dc.type | Article | en_US |
dc.rights.robots | IndexNoFollow | |
dc.subject.hlbsecondlevel | Dermatology | |
dc.subject.hlbtoplevel | Health Sciences | |
dc.description.peerreviewed | Peer Reviewed | |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/133546/1/cup12730_am.pdf | |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/133546/2/cup12730.pdf | |
dc.identifier.doi | 10.1111/cup.12730 | |
dc.identifier.source | Journal of Cutaneous Pathology | |
dc.identifier.citedreference | Hilliard NJ, Krahl D, Sellheyer K. p16 expression differentiates between desmoplastic Spitz nevus and desmoplastic melanoma. J Cutan Pathol 2009; 36: 753. | |
dc.identifier.citedreference | Hussussian CJ, Struewing JP, Goldstein AM, et al. Germline p16 mutations in familial melanoma. Nat Genet 1994; 8: 15. | |
dc.identifier.citedreference | Goldstein AM. Familial melanoma, pancreatic cancer and germline CDKN2A mutations. Hum Mutat 2004; 23: 630. | |
dc.identifier.citedreference | Kannengiesser C, Brookes S, del Arroyo AG, et al. Functional, structural, and genetic evaluation of 20 CDKN2A germ line mutations identified in melanoma‐prone families or patients. Hum Mutat 2009; 30: 564. | |
dc.identifier.citedreference | Della Torre G, Pasini B, Frigerio S, et al. CDKN2A and CDK4 mutation analysis in Italian melanoma‐prone families: functional characterization of a novel CDKN2A germ line mutation. Br J Cancer 2001; 85: 836. | |
dc.identifier.citedreference | FitzGerald MG, Harkin DP, Silva‐Arrieta S, et al. Prevalence of germ‐line mutations in p16, p19ARF, and CDK4 in familial melanoma: analysis of a clinic‐based population. Proc Natl Acad Sci U S A 1996; 93: 8541. | |
dc.identifier.citedreference | George E, Polissar NL, Wick M. Immunohistochemical evaluation of p16INK4A, E‐cadherin, and cyclin D1 expression in melanoma and Spitz tumors. Am J Clin Pathol 2010; 133: 370. | |
dc.identifier.citedreference | Al Dhaybi R, Agoumi M, Gagne I, McCuaig C, Powell J, Kokta V. p16 expression: a marker of differentiation between childhood malignant melanomas and Spitz nevi. J Am Acad Dermatol 2011; 65: 357. | |
dc.identifier.citedreference | Mason A, Wititsuwannakul J, Klump VR, Lott J, Lazova R. Expression of p16 alone does not differentiate between Spitz nevi and spitzoid melanoma. J Cutan Pathol 2012; 39: 1062. | |
dc.identifier.citedreference | Schouten B, Egeler RM, Leenen PJ, Taminiau AH, van den Broek LJ, Hogendoorn PC. Expression of cell cycle‐related gene products in Langerhans cell histiocytosis. J Pediatr Hematol Oncol 2002; 24: 727. | |
dc.identifier.citedreference | Kim SY, Kim HJ, Kim HJ, et al. Role of p16 in the pathogenesis of Langerhans cell histiocytosis. Korean J Hematol 2010; 45: 247. | |
dc.identifier.citedreference | Chilosi M, Facchetti F, Calio A, et al. Oncogene‐induced senescence distinguishes indolent from aggressive forms of pulmonary and non‐pulmonary Langerhans cell histiocytosis. Leuk Lymphoma 2014; 55: 2620. | |
dc.identifier.citedreference | Kato N, Ueno H. Intradermal Spitz nevus differentiated from reticulohistiocytic granuloma by immunoreactivity to S‐100 protein. J Dermatol 1990; 17: 569. | |
dc.identifier.citedreference | Miettinen M, Fetsch JF. Reticulohistiocytoma (solitary epithelioid histiocytoma): a clinicopathologic and immunohistochemical study of 44 cases. Am J Surg Pathol 2006; 30: 521. | |
dc.identifier.citedreference | Cohen PR, Lee RA. Adult‐onset reticulohistiocytoma presenting as a solitary asymptomatic red knee nodule: report and review of clinical presentations and immunohistochemistry staining features of reticulohistiocytosis. Dermatol Online J 2014; 20. | |
dc.identifier.citedreference | Badalian‐Very G, Vergilio JA, Degar BA, et al. Recurrent BRAF mutations in Langerhans cell histiocytosis. Blood 2010; 116: 1919. | |
dc.identifier.citedreference | Pollock PM, Harper UL, Hansen KS, et al. High frequency of BRAF mutations in nevi. Nat Genet 2003; 33: 19. | |
dc.identifier.citedreference | Michaloglou C, Vredeveld LC, Soengas MS, et al. BRAFE600‐associated senescence‐like cell cycle arrest of human naevi. Nature 2005; 436: 720. | |
dc.identifier.citedreference | Blokhin E, Pulitzer M, Busam KJ. Immunohistochemical expression of p16 in desmoplastic melanoma. J Cutan Pathol 2013; 40: 796. | |
dc.identifier.citedreference | Eilers G, Czaplinski JT, Mayeda M, et al. CDKN2A/p16 loss implicates CDK4 as a therapeutic target in imatinib‐resistant dermatofibrosarcoma protuberans. Mol Cancer Ther 2015; 14: 1346. | |
dc.identifier.citedreference | Miller K, Goodlad JR, Brenn T. Pleomorphic dermal sarcoma: adverse histologic features predict aggressive behavior and allow distinction from atypical fibroxanthoma. Am J Surg Pathol 2012; 36: 1317. | |
dc.identifier.citedreference | Knosel T, Altendorf‐Hofmann A, Lindner L, et al. Loss of p16(INK4a) is associated with reduced patient survival in soft tissue tumours, and indicates a senescence barrier. J Clin Pathol 2014; 67: 592. | |
dc.identifier.citedreference | Reynisdottir I, Massague J. The subcellular locations of p15(Ink4b) and p27(Kip1) coordinate their inhibitory interactions with cdk4 and cdk2. Genes Dev 1997; 11: 492. | |
dc.identifier.citedreference | Geradts J, Kratzke RA, Niehans GA, Lincoln CE. Immunohistochemical detection of the cyclin‐dependent kinase inhibitor 2/multiple tumor suppressor gene 1 (CDKN2/MTS1) product p16INK4A in archival human solid tumors: correlation with retinoblastoma protein expression. Cancer Res 1995; 55: 6006. | |
dc.identifier.citedreference | Nobori T, Miura K, Wu DJ, Lois A, Takabayashi K, Carson DA. Deletions of the cyclin‐dependent kinase‐4 inhibitor gene in multiple human cancers. Nature 1994; 368: 753. | |
dc.identifier.citedreference | Online Mendelian Inheritance in Man, OMIM. Johns Hopkins University, Baltimore, MD. URL http://omim.org/ [accessed on 7 January 2016]. | |
dc.identifier.citedreference | Liggett WH Jr, Sidransky D. Role of the p16 tumor suppressor gene in cancer. J Clin Oncol 1998; 16: 1197. | |
dc.identifier.citedreference | Collado M, Blasco MA, Serrano M. Cellular senescence in cancer and aging. Cell 2007; 130: 223. | |
dc.identifier.citedreference | Courtois‐Cox S, Jones SL, Cichowski K. Many roads lead to oncogene‐induced senescence. Oncogene 2008; 27: 2801. | |
dc.identifier.citedreference | Maldonado JL, Timmerman L, Fridlyand J, Bastian BC. Mechanisms of cell‐cycle arrest in Spitz nevi with constitutive activation of the MAP‐kinase pathway. Am J Pathol 2004; 164: 1783. | |
dc.identifier.citedreference | Sparrow LE, Eldon MJ, English DR, Heenan PJ. p16 and p21WAF1 protein expression in melanocytic tumors by immunohistochemistry. Am J Dermatopathol 1998; 20: 255. | |
dc.identifier.citedreference | Reed JA, Loganzo F Jr, Shea CR, et al. Loss of expression of the p16/cyclin‐dependent kinase inhibitor 2 tumor suppressor gene in melanocytic lesions correlates with invasive stage of tumor progression. Cancer Res 1995; 55: 2713. | |
dc.identifier.citedreference | Funk JO, Schiller PI, Barrett MT, Wong DJ, Kind P, Sander CA. p16INK4a expression is frequently decreased and associated with 9p21 loss of heterozygosity in sporadic melanoma. J Cutan Pathol 1998; 25: 291. | |
dc.identifier.citedreference | Richmond‐Sinclair NM, Lee E, Cummings MC, et al. Histologic and epidemiologic correlates of P‐MAPK, Brn‐2, pRb, p53, and p16 immunostaining in cutaneous melanomas. Melanoma Res 2008; 18: 336. | |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.